Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.
Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.
One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.
In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.
The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.
Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.
The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.
Aspira Women’s Health (Nasdaq: AWH) reported its Q1 2024 financial results. Key highlights include $2.2 million in OvaSuiteSM revenue and 5,829 units sold, with a 22% decrease in cash utilization compared to Q1 2023. Notably, OvaWatch volume grew 114% year-over-year, and gross margin reached 56% from 51% in the prior year. Aspira also saw significant decreases in R&D, sales and marketing, and general administrative expenses. The company ended the quarter with $3.7 million in cash, up from $2.9 million at the end of 2023, and raised $5.6 million through a direct offering. Key corporate developments include a study validating OvaWatch for ovarian cancer management, a new reimbursement agreement with Anthem Blue Cross, and the launch of OvaWatch’s longitudinal monitoring feature.
Aspira Women’s Health Inc. will announce its first-quarter earnings results for the period ending March 31, 2024, on May 15, 2024. The company, focused on developing gynecologic disease diagnostic tools, will also host a conference call on the same day to discuss financial results and provide a corporate update.
Aspira Women’s Health Inc. announced the publication of two peer-reviewed manuscripts related to OvaWatch, a tool for ovarian cancer risk assessment. The studies showed that OvaWatch can help in stratifying risk in patients with adnexal masses and monitoring ovarian cancer risk in women with low risk masses. The company aims to accelerate the adoption of OvaWatch as an alternative to surgical intervention for lower risk cases.
Aspira Women’s Health Inc. announced the formal launch of the updated OvaWatch ovarian cancer risk assessment test, utilizing an AI-powered algorithm to assess malignancy risk of adnexal masses. OvaWatch offers a negative predictive value of 99%, aiding physicians in determining the appropriate care plan over time. The longitudinal monitoring feature enhances the OvaWatch offering, providing a powerful tool for assessing malignancy risk in women with adnexal masses without the need for unnecessary surgery.
FAQ
What is the current stock price of Aspira Women's Health (AWH)?
What is the market cap of Aspira Women's Health (AWH)?
What is Aspira Women's Health Inc. known for?
What products does Aspira offer?
How effective is OvaWatch?
What is Ova1Plus?
What recent achievements has Aspira made?
What is EndoCheck?
How has Aspira performed financially recently?
Who leads Aspira Women's Health Inc.?
What is OvaMDx?
How does Aspira's test pipeline address women's health issues?
